Fatal hepatic veno-occlusive disease in a newborn infant.
We describe a newborn infant with veno-occlusive disease (VOD) of the liver. Prior to discharge from the hospital, the newborn, who had been treated for suspected neonatal infection, suddenly developed sepsis-like symptoms. The size of the liver as well as serum activity of hepatic enzymes increased progressively. Initial Doppler-flow studies demonstrated an absent flow in the vena portae, a finding that was compatible with vena portae thrombosis or occlusion of other hepatic veins. A therapy with recombinant tissue plasminogen activator (rt-PA) was initiated; due to extensive bleedings from various sides, the fibrinolytic therapy had to be withdrawn 12 hours later, when Doppler-flow examination revealed a reverse flow in hepatofugal direction. Despite supportive therapy, the general condition of the patient deteriorated continuously, finally resulting in liver and renal failure. Our patient died 19 days after birth. The autopsy demonstrated obliterative lesions of the centrilobular and sublobular hepatic veins, the classical signs of VOD of the liver. Despite extensive diagnostics and examinations, the etiology of VOD could not been elucidated in this newborn.
Seibold-Weiger
K
K
Department of Neonatology, University Children's Hospital, Tübingen, Germany.
Vochem
M
M
Mackensen-Haen
S
S
Speer
C
C
D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001424:Bacterial Infections / Q000175:diagnosis; D017809:Fatal Outcome; D006470:Hemorrhage / Q000139:chemically induced; D006503:Hepatic Veins / Q000473:pathology; D006504:Hepatic Veno-Occlusive Disease / Q000175:diagnosis* / Q000473:pathology; D006529:Hepatomegaly / Q000175:diagnosis; D006801:Humans; D007231:Infant, Newborn; D007770:L-Lactate Dehydrogenase / Q000097:blood; D017093:Liver Failure / Q000209:etiology; D008297:Male; D010960:Plasminogen Activators / Q000009:adverse effects / Q000627:therapeutic use; D011169:Portal Vein / Q000000981:diagnostic imaging; D051437:Renal Insufficiency / Q000209:etiology; D015912:Thrombolytic Therapy / Q000009:adverse effects; D013927:Thrombosis / Q000175:diagnosis; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use; D018608:Ultrasonography, Doppler
D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator